400th Patient Enrolled in Intrinsic Therapeutics Spine Device Trial

Intrinsic Therapeutics has enrolled the 400th patient in a level 1, prospective, randomized, multi-center clinical trial to evaluate the Barricaid Prosthesis for lumbar discectomy patients.

Advertisement

 

The study is being conducted in Germany, Switzerland, Austria and The Benelux to treat patients with sciatica. The project studies the safety and effectiveness of the Barricaid device and investigates clinical and radiographic information related to disc degeneration.

 

 

More Articles on Orthopedic and Spine Devices:
Lanx Publishes Favorable Study for ASPEN Minimally Invasive Spinal Fusion Device
Integra LifeSciences Receives FDA Clearance for Titan Reverse Shoulder System
DJO Global Posts $20.6M Net Loss in Q2

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.